Author:
Dimech Wayne, ,Lim Megan SC,Van Gemert Caroline,Guy Rebecca,Boyle Douglas,Donovan Basil,Hellard Margaret
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. National Notifiable Diseases Surveillance System. http://www9.health.gov.au/cda/source/cda-index.cfm ,
2. Black CM: Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev. 1997, 10 (1): 160-184.
3. Global incidence and prevalence of selected curable sexually transmitted infections- 2008. http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf ,
4. Adams EJ, LaMontagne DS, Johnston AR, Pimenta JM, Fenton KA, Edmunds WJ: Modelling the healthcare costs of an opportunistic chlamydia screening programme. Sex Transm Infect. 2004, 80 (5): 363-370. 10.1136/sti.2004.009654.
5. Honey E, Augood C, Templeton A, Russell I, Paavonen J, Mardh PA, Stary A, Stray-Pedersen B: Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect. 2002, 78 (6): 406-412. 10.1136/sti.78.6.406.